Valsartan / sacubitril

Active substance
Valsartan / sacubitril
Domain
Cardiovascular diseases
Reason of inclusion in Horizonscan Geneesmiddelen
Indication extension
Main indication
Other medication for cardiovascular diseases
Extended indication
Post acute Myocardial Infarction

1. Product

Proprietary name
Entresto
Manufacturer
Novartis
Mechanism of action
Combination therapy
Route of administration
Oral
Therapeutical formulation
Tablet
Budgetting framework
Extramural (GVS)
Additional comments
Entresto vertoont het werkingsmechanisme van een angiotensinereceptor-neprilysine-remmer door tegelijk neprilysine (neutrale endopeptidase, NEP) te remmen via LBQ657, de werkzame metaboliet van de prodrug sacubitril, en door de angiotensine II type 1-receptor (AT1-receptor) te blokkeren via valsartan.

2. Registration

Registration route
Centralised (EMA)
Submission date
November 2021
Expected Registration
November 2022
Orphan drug
No
Registration phase
Clinical trials

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
2 times a day

4. Expected patient volume per year

There is currently nothing known about the expected patient volume.

5. Expected cost per patient per year

Cost
1,800
References
Medicijnkosten.nl
Additional comments
€ 2,49 per tablet. Voor behandeling op jaarbasis: €1.815,95.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
Verwachte registratie HFpEF :2020, verwachte registratie MI: 2021.
References
Fabrikant (nov 2017)

9. Other information

There is currently no futher information available.